Literature DB >> 1167561

A radioimmunoassay for human antigen-antibody complexes in clinical material.

J S Cowdery, P E Treadwell, R B Fritz.   

Abstract

Soluble antigen-antibody complexes have been detected by a radioimmunoassay with rheumatoid factor as the primary antibody to bind 125-I immune complexes or heat aggregated IgG. Bound complexes are precipitated by rabbit anti-human IgM. The binding of the rheumatoid factor to the iodinated altered IgG can be inhibited by preincubation of the rheumatoid factor with human antigen-antibody complexes. The degree to which immune complexes inhibit the binding of rheumatoid factor to heat aggregated IgG has been shown to be dependent upon the antigen-antibody ratio of the complexes, with complexes formed at or near the point of equivalence exhibiting maximum inhibitory activity. Sera from individuals suffering from certain connective tissue disorders were found to inhibit the binding of rheumatoid factor to 125-I aggregrated IgG; sera from normal individuals did not inhibit this reaction when used at comparable dilutions. This procedure can be used as a relatively simple, reproducible means of detecting immune complexes in clinical specimens. The assay is sufficiently sensitive to detect 125 ng of soluble immune complexes.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1167561

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Circulating and intra-articular immune complexes in patients with rheumatoid arthritis. Correlation of 125I-Clq binding activity with clinical and biological features of the disease.

Authors:  R H Zubler; U Nydegger; L H Perrin; K Fehr; J McCormick; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

2.  Circulating immune complexes in ulcerative colitis. I. Correlation to disease activity.

Authors:  H Nielsen; V Binder; H Daugharty; S E Svehag
Journal:  Clin Exp Immunol       Date:  1978-01       Impact factor: 4.330

3.  Studies on circulating soluble immune complexes of the liver disease. 1. Inhibition assay of polyclonal rheumatoid factor binding to IgG-sepharose.

Authors:  J Narumoto; T Arima; K Kunishi; T Yasuhara; K Suwaki; H Shimomura; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1979-12

Review 4.  Immune complexes in human diseases: a review.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

5.  Studies on circulating soluble immune complexes of the liver disease. 2. Serum inhibitory activity of polyclonal rheumatoid factor binding to IgG-sepharose.

Authors:  J Narumoto; T Arima; K Kunishi; T Yasuhara; K Suwaki; H Shimomura; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1979-12

Review 6.  Pitfalls in the methodology for detection of immune complexes.

Authors:  R Heimer; S Per
Journal:  Surv Immunol Res       Date:  1982

Review 7.  Circulating immune complexes in dermatologic disease.

Authors:  T J Lawley; R P Hall
Journal:  Springer Semin Immunopathol       Date:  1981

8.  Detection of immune complexes. The use of radioimmunoassays with Clq and monoclonal rheumatoid factor.

Authors:  A Gabriel; V Agnello
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

9.  Studies on circulating soluble immune complexes of the liver disease. 6. Comparative studies of 125I-pRF inhibition assay, 125I-Clq inhibition assay and 125I-Clq binding assay.

Authors:  J Narumoto
Journal:  Gastroenterol Jpn       Date:  1981

10.  Inhibition of antibody-dependent cell-mediated cytotoxicity (ADCC) as a means of detection of immune complexes in the sera of patients with thyroid disorders and bronchogenic carcinoma.

Authors:  T Barkas; S F AL-Khateeb; W J Irvine; N M Davidson; P Roscoe
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.